LONDON: Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition.
Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). A critical accompanying editorial, however, may make some doctors think twice before writing prescriptions.
GSK said it did not believe the editorial presented an accurate picture of Trelegy’s benefit-risk profile, adding that the critique reflected the long-held views of Suissa.
The British drugmaker views Trelegy as a critical new product, along with shingles vaccine Shingrix, as it seeks to fill a revenue gap left by falling sales of the older lung drug Advair, which could face U.S. generic competition this year.
(Reporting by Ben Hirschler; Editing by Elaine Hardcastle)